About
Specialties:
- Drug Discovery (Preclinical & Early Clinical)
- R&D Management…
Activity
-
A parent's worst nightmare became reality. Ruth died in a psychiatric ward. Alone. Without her parents. Reading her story shook me to my core -…
A parent's worst nightmare became reality. Ruth died in a psychiatric ward. Alone. Without her parents. Reading her story shook me to my core -…
Liked by Lorenz Mayr
-
CAR-T with in-vivo delivery of mRNA-LNP for the treatment of aging & inflammation: Chimeric antigen receptor (CAR) technology, originally…
CAR-T with in-vivo delivery of mRNA-LNP for the treatment of aging & inflammation: Chimeric antigen receptor (CAR) technology, originally…
Shared by Lorenz Mayr
-
Good bye, Marc! With great sadness, we need to report that our friend, colleague and mentor Marc Lang has passed away on August 15, 2025. Marc has…
Good bye, Marc! With great sadness, we need to report that our friend, colleague and mentor Marc Lang has passed away on August 15, 2025. Marc has…
Shared by Lorenz Mayr
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
-
-
-
-
Languages
-
English
Full professional proficiency
-
German
Native or bilingual proficiency
More activity by Lorenz
-
I am excited to share that I’ve joined Applied StemCell as CEO and look forward to leading the organization through the next phase of its journey…
I am excited to share that I’ve joined Applied StemCell as CEO and look forward to leading the organization through the next phase of its journey…
Liked by Lorenz Mayr
-
The first approved checkpoint-targeting antibody cancer immunotherapy - Ipilimumab - came out of UC Berkeley. So did the foundations of the first…
The first approved checkpoint-targeting antibody cancer immunotherapy - Ipilimumab - came out of UC Berkeley. So did the foundations of the first…
Liked by Lorenz Mayr
-
𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦: Kite Makes $350M In Vivo CAR-T Acquisition 👇 Kite just announced the acquisition of Interius BioTherapeutics for $350…
𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦: Kite Makes $350M In Vivo CAR-T Acquisition 👇 Kite just announced the acquisition of Interius BioTherapeutics for $350…
Liked by Lorenz Mayr
-
Ultra-Personalized Genome Editing in Newborns (“N-of-1 Therapies“): Scientists have used a genome-editing technique called base editing to correct a…
Ultra-Personalized Genome Editing in Newborns (“N-of-1 Therapies“): Scientists have used a genome-editing technique called base editing to correct a…
Shared by Lorenz Mayr
-
🌍 Basel is on track to become Europe’s Silicon Valley of biotech innovation! Startups, pharma leaders and cutting-edge research are driving this…
🌍 Basel is on track to become Europe’s Silicon Valley of biotech innovation! Startups, pharma leaders and cutting-edge research are driving this…
Liked by Lorenz Mayr
-
Clinical Trials Are Booming - Here’s What’s Hot 👇 2024 smashed records in clinical research: 4,903 industry-sponsored trials wrapped up worldwide -…
Clinical Trials Are Booming - Here’s What’s Hot 👇 2024 smashed records in clinical research: 4,903 industry-sponsored trials wrapped up worldwide -…
Liked by Lorenz Mayr
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More